MarketBeat
22 Nov 2026, 17:12 UTC · 1h ago
AbCellera Biologics Targets 2027 Phase 3 Trial for Hot Flash Drug
Impact · against what's priced in
AbCellera provides a concrete timeline for its lead hot flash candidate ABCL635, shifting the focus to H1 2027 for the next binary catalyst. While the abandonment of the OX40 ligand program is a minor negative, the clarity on the Phase 3 path and the potential for a $12 billion market for non-hormonal treatments provide a long-term valuation framework.
- ABCL+0.40
No priced-in read yet
- In context
The company has established a mid-2027 target for Phase 3 trials of ABCL635 and expects further Phase 2 data in early 2027. This provides a definitive timeline for the registrational phase and a near-term catalyst, although the discontinuation of the OX40 ligand program is a modest offset.





